[144] Kiniksa Pharmaceuticals International, plc SEC Filing

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc (KNSA) Form 144 notifies proposed sales of 78,233 Class A ordinary shares through Charles Schwab & Co., with an aggregate market value of $2,588,711.00 and an approximate sale date of 08/14/2025 on NASDAQ. The filing states these shares were acquired the same day by employee stock option exercise and disposed via a broker cashless exercise. The filer previously sold 49,407 shares on 08/12/2025 for $1,600,641.00 and 50,129 shares on 08/13/2025 for $1,670,468.00. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.

Positive

• None.

Negative

• Concentrated insider selling over three consecutive days totaling 177,769 shares (78,233 proposed plus 99,536 prior) and roughly $5.86M in proceeds, which is notable for investor monitoring

Insights

Financial Analyst

TL;DR: Insider sold 78,233 shares by cashless exercise; combined recent sales exceed $3.2M, indicating notable insider liquidity.

The filing documents a routine disposition following an employee stock option exercise, executed as a cashless transaction through a broker. The proposed sale of 78,233 shares at an indicated market value of $2,588,711 on 08/14/2025, together with the two prior sales on 08/12 and 08/13 totaling 99,536 shares and roughly $3.27M in proceeds, represents concentrated insider selling over a short period. This is material to investor monitoring because clustered insider sales can alter short-term free float and may influence market perception, though the filing does not state any undisclosed operational issues.

Corporate Governance Expert

TL;DR: The sales are disclosed under Rule 144 and include the seller's attestation of no undisclosed material adverse information.

The document follows Rule 144 disclosure norms: it identifies the nature of acquisition as an employee stock option exercise, specifies broker-mediated cashless exercise payment, and contains the seller's representation regarding material information. From a governance perspective, the transaction appears procedurally compliant; the filing does not reference a Rule 10b5-1 plan or other trading instructions, and no compliance exceptions are noted.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A ordinary shares	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	78233	2588711.00	43472928	08/14/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A ordinary shares	08/14/2025	Employee Stock Option Exercise	Kiniksa Pharmaceuticals International, plc			78233	08/14/2025	Broker Payment for Cashless Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Thomas Malley 100 Hayden Avenue Lexington MA 02421	Kiniksa Pharmaceuticals International, plc	08/12/2025	49407	1600641.00
Thomas Malley 100 Hayden Avenue Lexington MA 02421	Kiniksa Pharmaceuticals International, plc	08/13/2025	50129	1670468.00

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What shares does the KNSA Form 144 propose to sell?

The filing proposes sale of 78,233 Class A ordinary shares on 08/14/2025 via Charles Schwab, NASDAQ, with aggregate market value $2,588,711.00.

How were the shares acquired that are being sold in the KNSA filing?

The shares were acquired on 08/14/2025 by employee stock option exercise and the sale is via a broker cashless exercise payment.

Did the filer sell other KNSA shares recently?

Yes. The filer sold 49,407 shares on 08/12/2025 for $1,600,641.00 and 50,129 shares on 08/13/2025 for $1,670,468.00.

Does the Form 144 state any undisclosed material adverse information?

The seller signs a representation that they do not know any material adverse information about the issuer that has not been publicly disclosed.

Through which broker will the proposed sale be executed?

The filing lists Charles Schwab & Co., Inc. at 3000 Schwab Way, Westlake, TX as the broker for the proposed sale.